ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2015

Abstract Number: 2354

The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors

Robert Terkeltaub1, Fernando Perez-Ruiz2,3,4, Jeff Kopicko5, Maple Fung5, Scott Adler6, Chris Storgard7, Scott Baumgartner5 and Nicola Dalbeth8, 1Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, 2Rheumatology Division, Hospital Universitario Cruces, Barakaldo, Spain, 3BioCruces Health Research Institute, Baracaldo, Spain, 4Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, 5Ardea Biosciences, Inc., San Diego, CA, 6AstraZeneca Pharmaceuticals, Wilmington, DE, 74939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, 8Department of Medicine, University of Auckland, Auckland, New Zealand

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2015

Date of first publication: September 29, 2015

Keywords: Allopurinol, Febuxostat, gout, hyperuricemia and tophaceous gout

Session Information

Date: Tuesday, November 10, 2015

Title: Metabolic and Crystal Arthropathies Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous studies have
shown that long-term urate-lowering therapy (ULT) is required for improvements
in gout flare frequency and tophi reduction, and that lower serum uric acid
(sUA) levels may result in greater benefit. However, optimal sUA levels to jointly
achieve these outcomes within a year using single or combination oral therapies
are uncertain, as they come mostly from observational studies. Lesinurad in
combination with a xanthine oxidase inhibitor (XOI) is highly effective in
reducing and sustaining sUA below target levels in Phase III studies. The
current analysis explored the relation between extent of reduction in sUA level
and efficacy and safety endpoints in these Phase III studies.

Methods: Patient data were combined from 3 Phase III clinical
studies on the efficacy and safety of lesinurad, a selective uric acid
reabsorption inhibitor (SURI), in combination with an XOI (allopurinol: CLEAR 1
[NCT01510158], CLEAR 2 [NCT01493531]), or febuxostat: CRYSTAL [NCT01510769]). For
the analyses, patients irrespective of treatment assignment were categorized by
their on-study median sUA level, which used all scheduled post-baseline sUAs
for each individual. Efficacy endpoints included clinical outcomes for ULT: tophus
size reduction and proportions of patients experiencing gout flares requiring
treatment (GFRT). Safety endpoints included treatment-emergent adverse events
(TEAEs).

Results: In total, 1537 patients
were eligible for efficacy analysis, including 474 patients with ≥1
target tophi at baseline. Patients with the lowest on-study median sUA levels
achieved the greatest reduction in tophus area at Month 12 and were least
likely to have GFRT during the last quarter of the study (Figure). GFRTs occurred in 11/90 (12.2%) of patients in the <3 mg/dL sUA
subgroup and in 137/689 (19.9%) of patients in the ≥5 mg/dL subgroup (Figure). TEAEs
occurred in 82/104 (78.8%) of patients in the <3 mg/dL sUA subgroup and in
671/886 (75.7%) of patients in the ≥5 mg/dL subgroup.

Conclusion: Based on a pooled analysis
of 3 Phase III clinical studies, patients with lower median on-study sUA experienced
greater reductions in tophus area, as well as a lower likelihood of having a
gout flare requiring treatment. A similar safety profile was noted irrespective
of the median sUA levels.



Disclosure: R. Terkeltaub, ARDEA/AstraZeneca, AstraZeneca, Takeda, Relburn, and REVIVE, 5; F. Perez-Ruiz, AstraZeneca, 8,Menarini, 5,AstraZeneca, 9,Menarini, 9,Cimabay, 9; J. Kopicko, Ardea Biosciences, 3; M. Fung, Ardea Biosciences, 3; S. Adler, AstraZeneca, 3; C. Storgard, Ardea Biosciences, 3; S. Baumgartner, Ardea Biosciences, 3; N. Dalbeth, AstraZeneca, 2,Fonterra, 2,Novartis Pharmaceutical Corporation, 2,Savient, 8,Menarini, 8,Novartis Pharmaceutical Corporation, 8,Teijin, 8,AstraZeneca, 9,Fonterra, 9,Pfizer Inc, 9,Takeda, 9,Metabolex, 9.

To cite this abstract in AMA style:

Terkeltaub R, Perez-Ruiz F, Kopicko J, Fung M, Adler S, Storgard C, Baumgartner S, Dalbeth N. The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-safety-and-efficacy-of-lower-serum-urate-levels-a-pooled-analysis-of-gout-subjects-receiving-lesinurad-and-xanthine-oxidase-inhibitors/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-safety-and-efficacy-of-lower-serum-urate-levels-a-pooled-analysis-of-gout-subjects-receiving-lesinurad-and-xanthine-oxidase-inhibitors/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology